# Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment

> **NCT07632209** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yayi He** · enrollment: 46 (estimated)

## Conditions studied

- SCLC, Extensive Stage

## Interventions

- **DRUG:** Lomustine
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT07632209
- **Lead sponsor:** Yayi He
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-06
- **Final completion:** 2028-12
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07632209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07632209, "Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07632209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*